home > ict > summer 2020 > regulatory challenges in global car t cell therapy development
International Clinical Trials

Regulatory Challenges in Global CAR T Cell Therapy Development

Since the historic approval of Kymriah® (tisagenlecleucel) in 2017, research on chimeric antigen receptor (CAR) T cell therapy has accelerated. There are more than 230 regenerative medicine companies in Europe and Israel, of which more than 140 are focused on cell therapies. Around the world, there were 452 clinical trials of genemodified and cell-based immunooncology therapies under way at the end of 2019 (1). Of these, 215 are in Phase II trials and 15 have progressed to Phase III trials.

Despite the bustle of research activity, only two CAR T cell therapies are on the market today, both targeting the CD19-expressing target cells, and clinical experience remains limited (2).

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:

There are no comments in regards to this article.

About the authors

Dr Brian Marks BSc, DC, has worked in clinical research for more than 20 years, and his extensive background covers the spectrum from single-site studies to large, multinational trials. He joined Premier Research in 2018 to oversee the oncology programme team, ensuring progress according to client and Premier Research requirements and driving courses of action to keep each programme on track. Brian received a Doctor of Chiropractic degree as well as a Bachelor of Science in Human Biology from Logan College of Chiropractic, US. He also holds a Bachelor of Arts in Psychology from the State University of New York, US.

Ashley Jones MSc joined the Premier Research team as a Senior Project Manager in 2017. Prior to her tenure with Premier Research, she worked for Quintiles for seven years. Ashley was integral in the creation of the Stem Cell Center of Excellence at Quintiles and currently helps develop strategies for CAR T and other immuno-oncology opportunities at Premier Research. Ashley’s therapeutic expertise includes Phase I-III oncology studies conducted in the US and globally, with a special interest in paediatric haematopoietic stem cell transplantation and graft versus host disease, as well as Phase I and II acute lymphoblastic leukaemia studies and advanced malignancies.
Print this page
Send to a friend
Privacy statement
News and Press Releases

Smart Bioprocessing with the new Eppendorf Control System

Hamburg, February 12, 2020 Working with flexible systems that evolve with the changing needs in a lab is indispensable. With the SciVario twin, Eppendorf, a key life science company, introduces its latest bioreactor control system for small- and bench-scale applications. The intelligent controller and new, innovative bay-drawer system enables the exchange of standardized modules to flexibly adapt the controller to the changing requirements in a laboratory.
More info >>

White Papers

Mauritius Island – An Emerging Centre for R&D in Biotechnology and the Life Sciences

CIDP (Centre International de Développement Pharmaceutique)

Mauritius, the tropical island situated in the Indian Ocean and known worldwide for its beautiful beaches, is also internationally recognised for its rule of law, and political and social stability. Over the past few years, the economy has been successfully transitioned from a monocrop to a diversified innovation-driven and knowledge-based economy, resting on agribusiness, export-oriented manufacturing, tourism, financial services, property development and real estate, ICT-BPO, the seafood industry, a free port, logistics and a nascent ocean economy. Emerging sectors such as healthcare and life sciences are presenting some niche areas for the taking, and the enabling environment is being put in place to make it happen - especially in the light of sustained growth within pharmaceutical, medical device, and clinical research. Important international players are already in operation locally as the country has established the appropriate legal and regulatory frameworks based on international norms, for the development of a strong biomedical research sector.
More info >>

Industry Events

CPhI Festival of Pharma

5-16 October 2020, Virtual

A virtual gathering for the pharmaceutical industry, the CPhI Festival of Pharma has been created to fill the gap left by in-person events at a time when travel and gatherings are off the cards.
More info >>



©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement